Sequential Release HydroLipo System for STING Gene Epigenetic Reprogramming and Immune Activation in Glioblastoma

Glioblastoma (GBM) remains a daunting oncological challenge because of its aggressive nature and resistance to conventional therapies. Inhibition of the intrinsic STING pathway in GBM hampers the effectiveness of immunotherapies. To overcome this clinical limitation, a Sequential Release HydroLipo System (SRHLS) is developed, in which hydrogels and nanoparticles are combined for controlled drug release. The SRHLS sequentially released decitabine and STING agonists, thereby correcting STING signaling dysfunction through epigenetic reprogramming and enhancing antitumor immunity. According to in vitro and in vivo experiments, the SRHLS reshaped the tumor microenvironment and markedly inhibited tumor growth, recurrence, and metastasis. These findings underscore the potential of the SRHLS as a promising therapeutic strategy for GBM.

Authors

Institutions

Publication Details

Journal
Advanced Science
Published
2024-12-11
DOI
https://doi.org/10.1002/advs.202408323
Citations
11
Primary Topic
interferon and immune responses
Type
article
Field-Weighted Citation Impact
2.65

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sequential Release HydroLipo System for STING Gene Epigenetic Reprogramming and Immune Activation in Glioblastoma

Xu Wang, Senxiang Yan, Qiuying Tang, Kan Jiang et al.
11 citations
Advanced Science
interferon and immune responses
2.65
article

Sequential Release HydroLipo System for STING Gene Epigenetic Reprogramming and Immune Activation in Glioblastoma

Xu Wang, Senxiang Yan, Qiuying Tang, Kan Jiang, Lingyun Wu, Jiangjie Wu, Si Chen, Wenjing Liu, Siyuan Wang, Xin Yin, Danfang Yan, Kaikai Ding, Cheng Wang, Hao Yu
article en
11 citations

Abstract

Glioblastoma (GBM) remains a daunting oncological challenge because of its aggressive nature and resistance to conventional therapies. Inhibition of the intrinsic STING pathway in GBM hampers the effectiveness of immunotherapies. To overcome this clinical limitation, a Sequential Release HydroLipo System (SRHLS) is developed, in which hydrogels and nanoparticles are combined for controlled drug release. The SRHLS sequentially released decitabine and STING agonists, thereby correcting STING signaling dysfunction through epigenetic reprogramming and enhancing antitumor immunity. According to in vitro and in vivo experiments, the SRHLS reshaped the tumor microenvironment and markedly inhibited tumor growth, recurrence, and metastasis. These findings underscore the potential of the SRHLS as a promising therapeutic strategy for GBM.

Advanced ScienceVol. 12(5)
First Affiliated Hospital Zhejiang University (CN), Zhejiang University of Technology (CN), Zhejiang University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province
Good health and well-being
Openalex Percentile: Top 9%
interferon and immune responses
2.65
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.